Peter Sleight

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint The ONTARGET/TRANSCEND Trial Programme: baseline data
    P Sleight
    Department of Cardiovascular Medicine, Level 5, John Radcliffe Hospital University of Oxford, UK
    Acta Diabetol 42:S50-6. 2005
  2. pmc No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Medscape J Med 10:S6. 2008
  3. ncbi request reprint New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension
    Peter Sleight
    The John Radcliffe Hospital, Oxford, UK and bHamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
    J Hypertens 21:1599-608. 2003
  4. doi request reprint Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
  5. pmc Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease
    Yan Liang
    Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
    CMAJ 184:E857-66. 2012
  6. doi request reprint Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment
    Paolo Verdecchia
    McMaster University, Population Health Research Institute, 237 Barton St E, Hamilton, ON L8L2X2 Canada
    Circulation 120:1380-9. 2009
  7. doi request reprint Cognitive impairment and risk of cardiovascular events and mortality
    Martin O'Donnell
    Population Health Research Institute, McMaster University, DBCVS Research Institute, Hamilton, Ontario, Canada
    Eur Heart J 33:1777-86. 2012
  8. doi request reprint Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme
    Tali Cukierman-Yaffe
    Population Health Research Institute, McMaster University, Canada
    Diabetes Res Clin Pract 83:387-93. 2009
  9. ncbi request reprint Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
    Koon Teo
    McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Am Heart J 148:52-61. 2004
  10. doi request reprint Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
    Peter Sleight
    CV Medicine, John Radcliffe Hospital, Oxford, UK
    J Hypertens 27:1360-9. 2009

Detail Information

Publications43

  1. ncbi request reprint The ONTARGET/TRANSCEND Trial Programme: baseline data
    P Sleight
    Department of Cardiovascular Medicine, Level 5, John Radcliffe Hospital University of Oxford, UK
    Acta Diabetol 42:S50-6. 2005
    ..These trials are the largest comparisons to date of ARB and ACE-inhibitor therapy in high-risk patients with controlled blood pressure, and the results will contribute significantly to the future treatment of cardiovascular disease...
  2. pmc No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Medscape J Med 10:S6. 2008
    ..The results of ONTARGET are anticipated to be available in 2008...
  3. ncbi request reprint New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension
    Peter Sleight
    The John Radcliffe Hospital, Oxford, UK and bHamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
    J Hypertens 21:1599-608. 2003
    ..We conclude that blood pressure decreasing per se is of clinical benefit, but drugs that block the renin-angiotensin system offer additional advantages. Drug choice is best determined by the patient's clinical condition...
  4. doi request reprint Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  5. pmc Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease
    Yan Liang
    Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
    CMAJ 184:E857-66. 2012
    ..We examined the association between moderate alcohol consumption and the risk of incident atrial fibrillation among older adults with existing cardiovascular disease or diabetes...
  6. doi request reprint Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment
    Paolo Verdecchia
    McMaster University, Population Health Research Institute, 237 Barton St E, Hamilton, ON L8L2X2 Canada
    Circulation 120:1380-9. 2009
    ..Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown...
  7. doi request reprint Cognitive impairment and risk of cardiovascular events and mortality
    Martin O'Donnell
    Population Health Research Institute, McMaster University, DBCVS Research Institute, Hamilton, Ontario, Canada
    Eur Heart J 33:1777-86. 2012
    ....
  8. doi request reprint Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme
    Tali Cukierman-Yaffe
    Population Health Research Institute, McMaster University, Canada
    Diabetes Res Clin Pract 83:387-93. 2009
    ..To assess the cross-sectional associations of the measures of glycemia and cognitive function in subjects at high cardiovascular risk...
  9. ncbi request reprint Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
    Koon Teo
    McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Am Heart J 148:52-61. 2004
    ..Currently, there is uncertainty about the role of ARBs when used alone or in combination with an ACE inhibitor in high-risk populations with controlled hypertension...
  10. doi request reprint Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
    Peter Sleight
    CV Medicine, John Radcliffe Hospital, Oxford, UK
    J Hypertens 27:1360-9. 2009
    ..We analysed the impact of BP on cardiovascular events in well treated high-risk patients enrolled in a large clinical trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)...
  11. ncbi request reprint Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial
    Eva Lonn
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario
    JAMA 293:1338-47. 2005
    ..Experimental and epidemiological data suggest that vitamin E supplementation may prevent cancer and cardiovascular events. Clinical trials have generally failed to confirm benefits, possibly due to their relatively short duration...
  12. doi request reprint Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
    J Hypertens Suppl 27:S23-9. 2009
    ..Thus, telmisartan provides comparable efficacy to ramipril with less adverse events, which may encourage patient compliance...
  13. ncbi request reprint Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients
    Eva Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Eur J Cardiovasc Prev Rehabil 10:420-8. 2003
    ..The prognostic significance of left ventricular hypertrophy (LVH) identified by simple electrocardiographic (ECG) criteria in high-risk patients with established cardiovascular (CV) diseases is not clearly understood...
  14. doi request reprint Urinary sodium and potassium excretion and risk of cardiovascular events
    MARTIN J O'DONNELL
    Population Health Research Institute, Hamilton General Hospital, McMaster University, 237 Barton St E, Third Floor, Hamilton, ON, L8L 2X2, Canada
    JAMA 306:2229-38. 2011
    ..The precise relationship between sodium and potassium intake and cardiovascular (CV) risk remains uncertain, especially in patients with CV disease...
  15. doi request reprint Influenza vaccination and major adverse vascular events in high-risk patients
    Jennie Johnstone
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Circulation 126:278-86. 2012
    ..We sought to determine the association between influenza vaccination and major adverse vascular events because the association remains uncertain...
  16. ncbi request reprint Effect of long-term therapy with ramipril in high-risk women
    Eva Lonn
    Department of Medicine, Division of Cardiology and Population Health Institute, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 40:693-702. 2002
    ..We evaluated the effects of long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor ramipril on major cardiovascular (CV) outcomes in high-risk women...
  17. ncbi request reprint Angiotensin II and trials of cardiovascular outcomes
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, England, Oxford, UK
    Am J Cardiol 89:11A-16A; discussion 16A-17A. 2002
    ....
  18. ncbi request reprint Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis
    Sébastien Foulquier
    aCARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands bKlinik für Innere Medizin III, University Clinic of the Saarland, Homburg Saar cDepartment of Nephrology and Hypertension, University of Erlangen Nurnberg, Erlangen, Germany dCardiovascular Medicine, John Radcliffe Hospital, Oxford, UK ePopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada fBoehringer Ingelheim Pharma GmbH and Co KG, Ingelheim am Rhein, Germany
    J Hypertens 32:1334-41. 2014
    ..We performed a post-hoc analysis to explore the hypothesis that telmisartan has a differential action in hypertensive vs. nonhypertensive patients...
  19. pmc Use of ramipril in preventing stroke: double blind randomised trial
    Jackie Bosch
    Canadian Cardiovascular Collaboration, McMaster University, 237 Barton St E, Hamilton, ON, Canada L8L 2X2
    BMJ 324:699-702. 2002
    ..To determine the effect of the angiotensin converting enzyme inhibitor ramipril on the secondary prevention of stroke...
  20. pmc Telmisartan to prevent recurrent stroke and cardiovascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 359:1225-37. 2008
    ..We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke...
  21. ncbi request reprint Benefits, challenges, and registerability of the polypill
    Peter Sleight
    Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
    Eur Heart J 27:1651-6. 2006
    ..Discussions with regulatory bodies are required in order to obtain some 'balance' between an overcautious registration approach and the potentially large public health benefits that are likely to arise from the use of polypills...
  22. ncbi request reprint Arterial baroreflexes can determine long-term blood pressure. Baroreceptors and hypertension: time for a re-think?
    Peter Sleight
    John Radcliffe Hospital, University of Oxford, UK
    Exp Physiol 89:337-41. 2004
  23. pmc The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
    Sarah Parish
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK
    Eur Heart J 30:2137-46. 2009
    ..The interdependence of these four risk factors is unclear...
  24. ncbi request reprint Blood-pressure reduction and cardiovascular risk in HOPE study
    P Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK
    Lancet 358:2130-1. 2001
    ....
  25. pmc The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    Lancet 377:2181-92. 2011
    ..The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients...
  26. ncbi request reprint Current options in the management of coronary artery disease
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Am J Cardiol 92:4N-8N. 2003
    ..Current options for the management of CAD have their limitations, thus confirming the appropriateness of continuing the search for improved therapies to reverse the disease process and reduce the global burden...
  27. ncbi request reprint The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension
    P Sleight
    Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, England
    Curr Cardiol Rep 3:511-8. 2001
    ..Nevertheless, there is a strong case for an attack on the renin-angiotensin system. Whether this will be by ACE inhibition, angiotensin-II receptor blockade, or both, is the subject of current clinical trials...
  28. ncbi request reprint Left ventricular hypertrophy in hypertensive patients is associated with abnormal rate adaptation of QT interval
    J P Singh
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, England, United Kingdom
    J Am Coll Cardiol 29:778-84. 1997
    ..This study sought to examine whether the responses of the QT interval to changes in the heart rate were altered in left ventricular hypertrophy (LVH)...
  29. ncbi request reprint Vasodilators after myocardial infarction-ISIS IV
    P Sleight
    Cardiac Department, John Radcliffe Hospital, Oxford, England
    Am J Hypertens 7:102S-105S. 1994
    ..Since it is not easy to identify all such patients in the first hours, a policy of initial treatment of all, then later reassessment, is safe and would produce the greatest overall benefit...
  30. ncbi request reprint Interdependence of blood pressure and heart period regulation in mild hypertension
    A J Coats
    Department of Cardiovascular Medicine, John Radcliffe Hospital, Headington, Oxford, England
    Am J Hypertens 4:234-8. 1991
    ..Thus, a more stable heart rate that results from an ineffective baroreflex is associated with a more variable systolic blood pressure...
  31. doi request reprint Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    Shamir R Mehta
    McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    Lancet 376:1233-43. 2010
    ..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI...
  32. doi request reprint Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  33. ncbi request reprint Who is fooling us?
    Peter Sleight
    Lancet 360:873-4. 2002
  34. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  35. ncbi request reprint Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial
    Gilles R Dagenais
    Laval University Heart and Lung Institute, Ste Foy, Quebec G1V 4G5, Canada
    Eur J Cardiovasc Prev Rehabil 12:75-81. 2005
    ..In recent large cardiovascular trials done in stable patients, 14-31% of the participants were smokers; the consequences of smoking in these trials using medications known to reduce cardiovascular events, have not been assessed...
  36. ncbi request reprint Predictors of adverse outcome among patients with hypertension and coronary artery disease
    Carl J Pepine
    Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 47:547-51. 2006
    ..We sought to determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD)...
  37. ncbi request reprint Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST)
    Issam Zineh
    Department of Pharmacy Practice, College of Pharmacy University of Florida, Gainesville, Florida 32610, USA
    Clin Cardiol 28:321-8. 2005
    ....
  38. pmc Preventing stroke with ramipril--authors' reply
    Salim Yusuf
    BMJ 326:52. 2003
  39. ncbi request reprint 1999 WHO/ISH Hypertension Guidelines--highlights & ESH update
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Hypertens 20:153-5. 2002
  40. ncbi request reprint 1999 WHO/ISH Hypertension Guidelines--highlights & ESH Update
    Sverre E Kjeldsen
    Blood Press 12:181-2. 2003
  41. doi request reprint Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy
    Sripal Bangalore
    Division of Cardiovascular Medicine, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    Am Heart J 156:241-7. 2008
    ..The purpose of the study was to compare a beta-blocker-based strategy with a heart rate-lowering calcium antagonists-based strategy in patients with prior MI...
  42. ncbi request reprint Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region
    Henry R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 23:1099-106. 2005
    ..To examine regional differences in the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial...